MEF2B
MEF2B (Myocyte-specific enhancer factor 2B) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and Mantle cell lymphoma.
Overview
Transcriptional activator which binds specifically to the MEF2 element, 5'-YTA[AT](4)TAR-3', found in numerous muscle-specific genes. Activates transcription via this element. May be involved in muscle-specific and/or growth factor-related transcription.
CIViC holds 2 clinical evidence items and 0 assertions across 1 variant. IntOGen calls it a driver in 5 cohorts (2 activating, 3 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma, Non-Hodgkin Lymphoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · MEF2B (Myocyte-specific enhancer factor 2B) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and Mantle cell lymphoma.
- 1 · What it is
MEF2B (Myocyte-specific enhancer factor 2B) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and Mantle cell lymphoma.
- 2 · What goes wrong in cancer
Transcriptional activator which binds specifically to the MEF2 element, 5'-YTA[AT](4)TAR-3', found in numerous muscle-specific genes. Activates transcription via this element.
- 3 · How drugs use it
No product in this corpus aims at MEF2B yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:6995 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q02080 (protein name, function text, keywords and locations (REST API)); CIViC gene MEF2B (2 evidence items, 0 assertions, 1 variants; diseases: Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000213999 (per-cancer scores at or above 0.5: non-Hodgkin lymphoma 0.56 (GraphQL API, CC0)); IntOGen MEF2B (driver in 5 cohorts (Act 2, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Transcriptional activator which binds specifically to the MEF2 element, 5'-YTA[AT](4)TAR-3', found in numerous muscle-specific genes. Activates transcription via this element. May be involved in muscle-specific and/or growth factor-related transcription. Location: Nucleus (UniProt). Locus 19p13.11 (HGNC).
- Non-Hodgkin lymphoma: Open Targets association 0.56 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 2 cohorts (MLYM, NHL)
- Diffuse large B-cell lymphoma: CIViC evidence names this disease; IntOGen driver in 3 cohorts (DLBCLNOS)
- Mantle cell lymphoma: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 2 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 3 cohorts; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"MEF2B" OR ABSTRACT:"MEF2B" OR TITLE:"myocyte enhancer factor 2B" OR ABSTRACT:"myocyte enhancer factor 2B" OR TITLE:"Myocyte-specific enhancer factor 2B" OR ABSTRACT:"Myocyte-specific enhancer factor 2B" OR TITLE:"RSRFR2" OR ABSTRACT:"RSRFR2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MEF2B, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetNFKBIE
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), CIViC, Diffuse large B-cell lymphoma.
- TargetPSMB8
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), CIViC, Open Targets Platform.
- TargetB2M
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), CIViC, Diffuse large B-cell lymphoma.
- TargetPSMD4
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), CIViC, Open Targets Platform.
- TargetBIRC3
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), CIViC, IntOGen.
- TargetSP140
Shares Mantle cell lymphoma, CIViC, IntOGen.
- TargetADRM1
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Open Targets Platform.
- TargetPSMA1
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Open Targets Platform.